ClinicalTrials.gg
CompletedNCT04464681Updated Aug 31, 2021

Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects

A Phase 1 interventional study of M201-A Injection and Placebo in Healthy Volunteers, sponsored by Kitasato University. Completed at 1 site in Japan. Open to male participants aged 20 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-31.

Sponsored by Kitasato University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2020, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
20 Years to 49 Years
Sex
Male
01

Study summary

This Phase I is designed to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of M201-A administered by multiple continuous intravenous injection in Healthy Japanese subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Kitasato University is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 49 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study

  • (1)Japanese Healthy Male subjects
  • (2)Age 20 to less than 50 years of age
  • (3)Body Weight of more than 50 kg, (BMI) of 18.5 to less than 25.0 kg/m2 at the screening examination
  • (4)Written must be obtained on a voluntary basis before any assessment is performed.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  • (1)Presence or past medical history of hepatic impairments, renal impairments, cardiovascular disease, gastrointestinal disease and others which are inappropriate for participating in this clinical trial
  • (2)Past medical history of cancer, cerebral infarction or cardiac infarction
  • (3)Past history of surgical operation of gastrointestine or kidney except appendectomy or hemorrhoid operation.
  • (4)Presence or past history of epilepsy.
  • (5)Presence or past medical history of allergic reactions or idiosyncrasies to food, medicinal substance and metallic materials
  • (6)heart rate(HR) >= 100 bpm at the screening examination
  • (7)The interval(QTcF) >= 440 ms at the screening examination
  • (8)brain natriuretic peptide(BNP) > 40 pg/mL at the screening examination
  • (9)K\<3.6 mEq/L at the screening examination
  • (10)Past history or suspect of aldosteronism.
  • (11)Any risk factors of Torsades de Pointes including such as heart failure, hypokalemia, long QT interval syndrome due to family medical history
  • (12)Cre>1.10 mg/dL, \<0.85 mg/dL at the screening examination
  • (13)Subject who donated whole blood of 400 mL within 12 weeks or whole blood of 400 mL of 200 mL / blood component donation within 4weeks prior to the first administration.
  • (14)Use of prescription drug, over-the-counter medications (except eye drops for dryness, sanitizer for preventing infection), or herbal medication within 4 weeks prior to study medication.
  • (15)Subject who consumed furanocoumarin containing food within 7 days prior to study medication.
  • (16)Subject who drunk alcohol or caffeine containing drink within 3 days prior to study medication.
  • (17)Subject who was administered of another drug within16 weeks prior to agree to participate in this study.
  • (18)Subject who was administered M201-A in the past.
  • (19)Subject who smoke within 90 day prior to study medication or who cannot quit smoking during the study period.
  • (20)Subject with positive result in (HB)s antigen, virus(HCV) antibody, antigen/antibody, Syphilis serum, urine drug test at the screening test. Subject with positive result in Coronavirus(COVID-19) test at the screening or at the hospitalization.
  • (21) Presence or past history of drug/alcohol abuse.
  • (22)Subject who do not use medically acceptable method until 90 days after the final study drug administration.
  • (23)Subject who investigator judges ineligible for other reasons
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    M201-A Injection

    Active Substance: M201-A Route of administration: continuous intravenous injection

    Drug: M201-A Injection

  • Placebo comparator
    Placebo

    Placebo: M201-A Placebo Route of administration: continuous intravenous injection

    Drug: Placebo

Interventions

  • DrugM201Studies of M201M201 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Active Substance: M201-A Route of administration: continuous intravenous injection

  • DrugPlacebo

    Placebo: M201-A Placebo Route of administration: continuous intravenous injection

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events as a measure of safety and tolerability

    Number of participants with adverse events, serious adverse events, physical examinations, vital sign measurements, 12-lead ECGs, Holter ECG, clinical laboratory safety tests (including hematology, chemistry, and urinalysis), recording of concomitant medications and procedures.

    Time frame: Throughout the study duration up to day 11

07

Study locations

1 site
  • Clinical Trial Center, Department of Research, KITASATO UNIVERSITY KITASATO INSTITUTE HOSPITAL
    Tokyo, 108-8642, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Nov 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2020
First posted
Jul 9, 2020
StartActual
Mar 30, 2020
Primary completionActual
Nov 28, 2020
CompletionActual
Nov 30, 2020
Last update
Aug 31, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04464681
Lead sponsor
Kitasato University
Collaborators
Aetas Pharma Co. Ltd.
Responsible party
Tomoko Hasunuma (Director of Clinical Trial Center, Kitasato University) — Principal investigator
First posted
Jul 9, 2020
Start date
Mar 30, 2020
Primary completion
Nov 28, 2020
Completion
Nov 30, 2020
Last update
Aug 31, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: M201

Start the discussion